Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Financial Performance - Q4 2024 sales growth of 10.3% at CER, with business EPS of €1.31 [1] - FY 2024 sales growth of 11.3% at CER, totaling €41.1 billion, exceeding sales targets [4] - Business EPS for FY 2024 reached €7.12, a 4.1% increase at CER, surpassing guidance [4] - IFRS net income for FY 2024 was €41,081 million, an 8.6% increase [3] - Free cash flow for FY 2024 was €5,955 million, a 19.6% decrease [6] Pipeline and R&D - Increased R&D investment to €7.4 billion, up 14.6% in 2024 [4] - Significant pipeline progress, including positive phase 3 results for rilzabrutinib and tolebrutinib [3] - 14 regulatory approvals for medicines and vaccines in 2024, with 21 regulatory submission acceptances [4] - Dupixent expected to reach sales of around €22 billion by 2030 [3] Strategic Initiatives - Intention to sell a controlling stake in Opella consumer health, expected to close in Q2 2025 [2] - Plan to execute a €5 billion share buyback program in 2025 [5] - Focus on becoming a science-driven biopharma company, supported by ongoing launches and pipeline developments [3] Product Performance - Dupixent sales increased by 16.0% to €3.5 billion in 2024 [4] - Beyfortus achieved blockbuster status with €1.7 billion in sales in its first full year [4] - Pharma launches contributed 11% of total sales, with ALTUVIIIO leading the growth [4] - Vaccines sales grew by 10.8% to €2.2 billion, driven by Beyfortus in Europe [4] Future Outlook - Anticipated mid-to-high single-digit percentage sales growth at CER in 2025 [5] - Expected strong rebound in business EPS with low double-digit percentage growth at CER in 2025 [5] - Confidence in mid-to-long-term growth prospects, supported by ongoing launches and pipeline developments [3] Dividend and Shareholder Returns - Proposed dividend of €3.92 for 2024, marking the 30th consecutive year of dividend increases [4]